During a press conference Tuesday at the International AIDS Conference in Vienna, Anthony Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases at NIH, describes the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial. The study is testing the safety and efficacy of microbicide gel containing the ARV drug tenofovir, and oral tablets containing tenofovir or a combination of tenofovir and emtricitabine known by the brand name Truvada.
In the Kingdom of eSwatini, the nation formerly known as Swaziland, where the percentage of the population who live with HIV is estimated to be the […]
United Nations, New York — Global tuberculosis advocates who converged on the United Nations and UN missions this week for the civil society hearing of the […]
Tools to diagnose and monitor HIV, hepatitis B and C, and tuberculosis, as well as resistance to first-line TB treatment are among the tests included in […]
Brushing aside White House proposals to cut global HIV and other international disease response funding, members of the House Appropriations Labor, Health and Human Services, Education […]